Dong-sheng S. Zhang

651 Dongfeng East Road
Guangzhou, 510060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 73 publications

Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial.

Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 05, 2026

Real-World Efficacy of Nab-Paclitaxel Plus Capecitabine and a PD-1 Inhibitor in Metastatic or Locally Advanced Esophageal Cancer.

Real-World Efficacy of Nab-Paclitaxel Plus Capecitabine and a PD-1 Inhibitor in Metastatic or Locally Advanced Esophageal Cancer.

Journal: Cancer medicine

Published: October 13, 2025

A temporal paradox in the proposed risk-adjusted surveillance algorithm for metastatic colorectal cancer.

A temporal paradox in the proposed risk-adjusted surveillance algorithm for metastatic colorectal cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 24, 2025

Prognostic nomogram for patients with HER2-negative metastatic gastric cancer receiving first-line PD-1 blockade.

Prognostic nomogram for patients with HER2-negative metastatic gastric cancer receiving first-line PD-1 blockade.

Journal: ESMO open

Published: May 13, 2025

Safety and efficacy of perioperative dual PD-1 and HER2 blockade in HER2-positive gastric cancer.

Safety and efficacy of perioperative dual PD-1 and HER2 blockade in HER2-positive gastric cancer.

Journal: Cell reports. Medicine

Published: January 14, 2025

Author Correction: Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial.

Author Correction: Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial.

Journal: Nature medicine

Published: January 08, 2024

Circular RNA circNCOA3 promotes tumor progression and anti-PD-1 resistance in colorectal cancer.

Circular RNA circNCOA3 promotes tumor progression and anti-PD-1 resistance in colorectal cancer.

Journal: Cancer drug resistance (Alhambra, Calif.)

Published: December 07, 2023

Exploring ALK fusion in colorectal cancer: a case series and comprehensive analysis.

Exploring ALK fusion in colorectal cancer: a case series and comprehensive analysis.

Journal: NPJ precision oncology

Published: December 06, 2023

XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.

XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.

Journal: Signal transduction and targeted therapy

Published: September 11, 2023

Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial.

Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial.

Journal: Nature medicine

Published: July 30, 2023

Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial.

Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial.

Journal: Nature medicine

Published: June 20, 2023

Safety of an inactivated COVID-19 vaccine (CoronaVac) in children aged 7-14 years in Taizhou, China.

Safety of an inactivated COVID-19 vaccine (CoronaVac) in children aged 7-14 years in Taizhou, China.

Journal: Diagnostic microbiology and infectious disease

Published: May 05, 2023

Showing 1-12 of 73

Last Updated: 09/26/2026